Premium
Diffuse alveolar hemorrhage following administration of tirofiban or abciximab: A nemesis of platelet glycoprotein IIb/iIIa inhibitors
Author(s) -
Ali Arshad,
Patil Sandish,
Grady Kevin J.,
Schreiber Theodore L.
Publication year - 2000
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/(sici)1522-726x(200002)49:2<181::aid-ccd14>3.0.co;2-j
Subject(s) - abciximab , tirofiban , medicine , diffuse alveolar hemorrhage , complication , pulmonary hemorrhage , platelet inhibition , platelet , cardiology , anesthesia , myocardial infarction , platelet aggregation , lung , percutaneous coronary intervention
We describe three patients who developed severe pulmonary hemorrhage following administration of tirofiban (one patient) and abciximab (two patients). Pulmonary hemorrhage associated with abciximab use has been described, but to the best of our knowledge there has been no previous reports of this complication with tirofiban. Cathet. Cardiovasc. Intervent. 49:181–184, 2000. © 2000 Wiley‐Liss, Inc.